-

10:47:16 PM

IPHA Stock News

IPHA - Innate Pharma

05/26/23 1:00 AM

Nasdaq : IPHA

clinical trial

Innate Pharma Highlights Phase 1/2 Dose Escalation Safety and Preliminary Efficacy of Sanofi Developed First NK Cell Engager SAR’579 / IPH6101 in R/R AML

Innate Pharma SA announced today that the abstract entitled“ A first-in-human study of CD123 NK Cell Engager SAR443579 in relapsed or refractory acute myeloid leukemia, B-cell acute lymphoblastic leukemia or high risk-myelodysplasia” was published on the ASCO 2023 Annual Meeting website. The abstract concludes that SAR’ 579, in development by Sanofi, was...

RHEA-AI

positive

05/23/23 1:00 AM

Nasdaq : IPHA

conferences

Innate Pharma to Participate in Upcoming Investor Conferences

Innate Pharma SA today announced that members of its senior management team are scheduled to participate in the following upcoming conferences:. American Society for Clinical Oncology 2023 Annual Meeting Event Date: June 2-5, Chicago Jefferies Healthcare Conference 2023 Event Date: June 7-9, New-York Goldman Sachs 44 th Annual Global Healthcare...

RHEA-AI

neutral

05/15/23 1:00 AM

Nasdaq : IPHA

conferencesclinical trial

Innate Pharma to Present IPH6501 Preclinical Data at The EHA 2023 Congress

Innate Pharma SA today announced that new preclinical data on its IPH6501 tetra-specific ANKET ® have been selected for oral presentation at the European Hematology Association 2023 congress, being held 8 to 15 June 2023 in Frankfurt, Germany. ANKET ® is Innate’ s proprietary platform for developing next-generation, multi-specific natural killer cell...

RHEA-AI

neutral

05/12/23 4:00 PM

Nasdaq : IPHA

Outcome of Innate Pharma’s 2023 Annual General Meeting

Innate Pharma SA announced the voting results of its shareholders at the Annual General Meeting, which took place on May 12, 2023, in Marseille. A total of 112 votes were cast out of a total of 36,142,912 shares giving right to 36,618,940 voting rights, representing a quorum of 44.928%. Headquartered in Marseille, France with a US office in Rockville, MD, Innate...

RHEA-AI

neutral

05/10/23 1:00 AM

Nasdaq : IPHA

earnings

Innate Pharma Reports First Quarter 2023 Financial Results and Business Update

Innate Pharma SA today reported its consolidated financial results for the quarter ending March 31, 2023.. “Our strong cash position was further bolstered during the first quarter of 2023 as we signed a license agreement with Takeda for antibody drug conjugates using a panel of selected Innate antibodies, with a primary focus in Celiac disease.

RHEA-AI

very positive

05/09/23 1:00 AM

Nasdaq : IPHA

Number of shares and voting rights of Innate Pharma as of May 1, 2023

Pursuant to the article L. 233-8 II of the French“ Code de Commerce” and the article 223-16 of the French stock-market authorities General Regulation, Innate Pharma SA releases its total number of shares outstanding as well as its voting rights as at May 1, 2023:. The total number of theoretical voting rights is used as the basis for calculating the crossing of...

RHEA-AI

neutral

05/03/23 1:00 AM

Nasdaq : IPHA

Innate Pharma Highlights Clinical Abstracts Selected for ASCO 2023 Annual Meeting

Innate Pharma SA announced today three abstracts including Innate’ s product candidates have been accepted for the American Society for Clinical Oncology 2023 Annual Meeting, taking place June 2-6, 2023 in Chicago, IL.. One abstract for SAR’ 579, currently developed by Sanofi, has been selected for oral presentation. Abstract: 7005 Abstract Title: A...

RHEA-AI

positive

05/03/23 1:00 AM

Nasdaq : IPHA

Innate Pharma Announces Conference Call and Webcast for Q1 Business Update

Innate Pharma SA, today announced that the Company will hold a conference call on Wednesday, May 10, 2023 at 2 p.m. EDT, to give an update on business progress during the first quarter of 2023.. Participants during the call will be:.

RHEA-AI

neutral

04/26/23 4:50 PM

Nasdaq : IPHA

Innate Pharma Establishes a New At-The-Market (“ATM”) Program on Nasdaq

Innate Pharma SA today announced that it has filed a prospectus supplement with the Securities and Exchange Commission relating to a new At-The-Market program. Pursuant to this program, the Company may offer and sell to eligible investors a total gross amount of up to $75 million of American Depositary Shares, each ADS representing one ordinary share of...

RHEA-AI

neutral

04/21/23 1:00 AM

Nasdaq : IPHA

conferences

Innate Pharma to Participate in Upcoming Investor Conference

Innate Pharma is a trusted partner to biopharmaceutical companies such as Sanofi and AstraZeneca, as well as leading research institutions, to accelerate innovation, research and development for the benefit of patients. Headquartered in Marseille, France with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the US.

RHEA-AI

neutral

1 2 3 4 5 6 7 8 9 10 Next